U.S. markets open in 5 hours 18 minutes
  • S&P Futures

    4,392.00
    -2.50 (-0.06%)
     
  • Dow Futures

    34,894.00
    -59.00 (-0.17%)
     
  • Nasdaq Futures

    14,932.50
    -15.25 (-0.10%)
     
  • Russell 2000 Futures

    2,194.10
    +7.40 (+0.34%)
     
  • Crude Oil

    71.87
    +0.22 (+0.31%)
     
  • Gold

    1,801.90
    +2.10 (+0.12%)
     
  • Silver

    24.77
    +0.12 (+0.49%)
     
  • EUR/USD

    1.1809
    -0.0017 (-0.14%)
     
  • 10-Yr Bond

    1.2340
    0.0000 (0.00%)
     
  • Vix

    19.23
    +1.65 (+9.39%)
     
  • GBP/USD

    1.3866
    -0.0013 (-0.09%)
     
  • USD/JPY

    109.9730
    +0.2060 (+0.19%)
     
  • BTC-USD

    39,797.96
    +2,654.27 (+7.15%)
     
  • CMC Crypto 200

    934.72
    +58.49 (+6.67%)
     
  • FTSE 100

    7,000.00
    +3.92 (+0.06%)
     
  • Nikkei 225

    27,581.66
    -388.56 (-1.39%)
     

Why Tabula Rasa Healthcare (TRHC) is Poised to Beat Earnings Estimates Again

·3 min read

Have you been searching for a stock that might be well-positioned to maintain its earnings-beat streak in its upcoming report? It is worth considering Tabula Rasa Healthcare (TRHC), which belongs to the Zacks Medical Info Systems industry.

This developer of health care software has an established record of topping earnings estimates, especially when looking at the previous two reports. The company boasts an average surprise for the past two quarters of 123.61%.

For the most recent quarter, Tabula Rasa Healthcare was expected to post earnings of $0.04 per share, but it reported $0.13 per share instead, representing a surprise of 225%. For the previous quarter, the consensus estimate was $0.18 per share, while it actually produced $0.22 per share, a surprise of 22.22%.

Price and EPS Surprise

Thanks in part to this history, there has been a favorable change in earnings estimates for Tabula Rasa Healthcare lately. In fact, the Zacks Earnings ESP (Expected Surprise Prediction) for the stock is positive, which is a great indicator of an earnings beat, particularly when combined with its solid Zacks Rank.

Our research shows that stocks with the combination of a positive Earnings ESP and a Zacks Rank #3 (Hold) or better produce a positive surprise nearly 70% of the time. In other words, if you have 10 stocks with this combination, the number of stocks that beat the consensus estimate could be as high as seven.

The Zacks Earnings ESP compares the Most Accurate Estimate to the Zacks Consensus Estimate for the quarter; the Most Accurate Estimate is a version of the Zacks Consensus whose definition is related to change. The idea here is that analysts revising their estimates right before an earnings release have the latest information, which could potentially be more accurate than what they and others contributing to the consensus had predicted earlier.

Tabula Rasa Healthcare currently has an Earnings ESP of +2,180.09%, which suggests that analysts have recently become bullish on the company's earnings prospects. This positive Earnings ESP when combined with the stock's Zacks Rank #3 (Hold) indicates that another beat is possibly around the corner. We expect the company's next earnings report to be released on May 7, 2020.

Investors should note, however, that a negative Earnings ESP reading is not indicative of an earnings miss, but a negative value does reduce the predictive power of this metric.

Many companies end up beating the consensus EPS estimate, though this is not the only reason why their shares gain. Additionally, some stocks may remain stable even if they end up missing the consensus estimate.

Because of this, it's really important to check a company's Earnings ESP ahead of its quarterly release to increase the odds of success. Make sure to utilize our Earnings ESP Filter to uncover the best stocks to buy or sell before they've reported.


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
Tabula Rasa Healthcare Inc. (TRHC) : Free Stock Analysis Report
 
To read this article on Zacks.com click here.